Amgen (NASDAQ: AMGN)
$306.71
(-1.6%)
-$4.84
Price as of April 1, 2025, 3:58 p.m. ET
Key Data Points
Current Price
$306.71
Daily Change
(-1.6%) -$4.84
Day's Range
$305.10 - $312.57
Previous Close
$306.92
Open
$310.58
Beta
0.49
Volume
3,042,271
Average Volume
3,138,897
Sector
Market Cap
$167B
Market Cap / Employee
$6M
52wk Range
$253.30 - $346.85
Revenue
$33B
Gross Margin
66.05%
Dividend Yield
2.9%
EPS
$7.55
CAPs Rating
-
Industry
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Amgen Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Amgen Company Info
One of the pioneers of the biotech industry, Amgen is now one of the world's largest pharmaceutical companies, with more than a dozen products focused on cancer, inflammation, neurology, cardiology, and more.
News & Analysis
The Fool has written over 500 articles on Amgen.
Featured Article
Got $5,000? These 3 Nasdaq Stocks Are Dirt Cheap Buys Right Now
David Jagielski | Apr 3, 2025
Featured Article
2 Surefire Dividend Stocks That Could Pay You for Life
Prosper Junior Bakiny | Mar 27, 2025
Which Dow Jones Stock Is Cheaper, Amgen or Merck?
Dan Victor | Mar 26, 2025
Prediction: These 2 Stocks Will Outperform the Market Through 2030
Prosper Junior Bakiny | Mar 17, 2025
2 Dividend Stocks to Buy for a Lifetime of Passive Income
Prosper Junior Bakiny | Mar 4, 2025
This Could Be the Best GLP-1 Stock to Buy in 2025
David Jagielski | Feb 26, 2025
These 3 Dow Jones Stocks Are Crushing It in 2025. Are They Still Buys?
Keith Speights | Feb 25, 2025
Amgen Surpasses Q4 Earnings Forecasts
JesterAI | Feb 4, 2025
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes

Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy
Why Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.
Todd Campbell | Sep 6, 2019

Why Amgen Can Deliver Medical and Financial Miracles
Its size, catalog, and pipeline give it strengths that are hard to beat.
Motley Fool Staff | Apr 9, 2019

Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018
Key trials suggest doctors may change how they treat patients with cardiovascular disease.
Motley Fool Staff | Dec 17, 2018
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.